Cargando…
Efficacy and safety of sorafenib for advanced renal cell carcinoma: real-world data of patients with renal impairment
BACKGROUND: We retrospectively analysed the efficacy and safety of sorafenib in patients with advanced renal cell carcinoma with renal impairment. METHODS: Patients were divided into two groups by an estimated glomerular filtration rate (eGFR) cut-off of 45 mL/min/1.73 m(2). Background factors consi...
Autores principales: | Tatsugami, Katsunori, Oya, Mototsugu, Kabu, Koki, Akaza, Hideyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5922406/ https://www.ncbi.nlm.nih.gov/pubmed/29721212 http://dx.doi.org/10.18632/oncotarget.24779 |
Ejemplares similares
-
Evaluation of efficacy and safety of sorafenib in kidney cancer patients aged 75 years and older: a propensity score-matched analysis
por: Tatsugami, Katsunori, et al.
Publicado: (2018) -
RETRACTED ARTICLE: Effectiveness and safety of sorafenib for renal cell, hepatocellular and thyroid carcinoma: pooled analysis in patients with renal impairment
por: Oya, Mototsugu, et al.
Publicado: (2022) -
A large-scale prospective registration study of the safety and efficacy of sorafenib tosylate in unresectable or metastatic renal cell carcinoma in Japan: results of over 3200 consecutive cases in post-marketing all-patient surveillance
por: Akaza, Hideyuki, et al.
Publicado: (2015) -
Real-world use of sunitinib in Japanese patients with advanced renal cell carcinoma: efficacy, safety and biomarker analyses in 1689 consecutive patients
por: Akaza, Hideyuki, et al.
Publicado: (2015) -
Efficacy and safety of subsequent molecular targeted therapy after immuno-checkpoint therapy, retrospective study of Japanese patients with metastatic renal cell carcinoma (AFTER I-O study)
por: Tomita, Yoshihiko, et al.
Publicado: (2021)